Myles David C.

Chief Discovery Officer Myles David C. sells 110,000 shares (16.9% of holdings) across 5 transactions for $3.1M at blended average $28.25

Myles David C., Chief Discovery and Non-Clinical Development Officer, executed 5 separate sales totaling 110,000 shares (110.0K shares) for $3,107,229.17 over three trading days (Jan 12-14, 2026) at prices ranging from $27.60 to $28.99, with a blended average price of $28.25. This represents a 16.9% reduction in his pre-transaction holdings of 652,761 shares, leaving him with 542,761 shares post-transaction. The sales occurred while the stock has declined 19.7% from its 52-week high of $35.83 and is currently trading at $28.77, near the lower end of the transaction range. Notably, Olema is unprofitable with a net loss of $42,217,000.00 over its most recent full fiscal year, providing operational context for insider liquidity activity. Prior trades by this insider at OLMA (three sells on 2025-12-19) have insufficient measurable history to assess timing patterns at this specific ticker.

Chief Discovery Officer sells 51,000 OLMA shares for $1.6M at $30.46 avg; retains 542.9K shares post-transaction.

Myles David C., Chief Discovery Officer, executed 3 separate sales totaling 51,000 shares for $1,553,543.54 at a blended average price of $30.46 on 2025-12-19. The shares were sold across three tranches at prices ranging from $28.08 to $31.39, representing an 8.6% reduction from his pre-transaction holdings of 593.9K shares. Notably, the transaction occurred when the stock was trading at $27.67, approximately 9% below the blended sale price, and 22.8% below its 52-week high of $35.83. The company remains unprofitable with a full-year net income of $-42.2M, while the insider retained substantial holdings of 542.9K shares post-transaction, suggesting continued material exposure to the company despite the sale.